About Sentynl therapeutics, inc.
Sentynl Therapeutics, Inc. is a US-based specialty pharmaceutical company that is committed to improving patient care through innovative therapeutics. The company was founded in 2016 and has since then been at the forefront of developing and commercializing novel treatments for various medical conditions.
At Sentynl Therapeutics, the focus is on developing therapies that address unmet medical needs and improve patient outcomes. The company's portfolio includes products for pain management, addiction treatment, and other therapeutic areas.
One of Sentynl's flagship products is Oxtellar XR (oxcarbazepine), an extended-release tablet used to treat partial seizures in adults and children over six years old. Oxtellar XR has been shown to be effective in reducing seizure frequency while also being well-tolerated by patients.
Another product in Sentynl's portfolio is Zubsolv (buprenorphine/naloxone), a sublingual tablet used for the maintenance treatment of opioid dependence. Zubsolv has been designed to provide a more convenient dosing regimen than other buprenorphine/naloxone products while also being highly effective in reducing opioid cravings.
Sentynl Therapeutics' commitment to innovation extends beyond its product portfolio. The company invests heavily in research and development, with a focus on identifying new therapeutic targets and developing novel drug delivery technologies.
In addition to its R&D efforts, Sentynl also places great emphasis on ensuring that its products are accessible to patients who need them most. The company works closely with healthcare providers, payers, and patient advocacy groups to ensure that its therapies are available at an affordable cost.
Overall, Sentynl Therapeutics' dedication to improving patient care through innovative therapeutics makes it one of the most promising companies in the specialty pharmaceutical industry today. With a strong pipeline of products under development and a commitment to making these therapies accessible to all patients who need them, Sentynl is poised for continued success as it works towards its mission of improving patient outcomes across multiple therapeutic areas.